Challenges in Multiple Myeloma Therapy in Older and Frail Patients

Area of Science:

• Hematology
• Oncology
• Geriatrics

Background:

• Multiple myeloma (MM) incidence is rising globally, especially in males over 50.
• Despite treatment advances, MM remains largely incurable, posing significant mortality.
• Elderly patients (>75 years) with MM often present with frailty, increasing vulnerability.

Purpose of the Study:

• To review the management strategies for frail multiple myeloma patients.
• To emphasize the importance of assessing fitness and frailty in MM care.
• To advocate for flexible therapeutic approaches tailored to individual patient needs.

Main Methods:

• Systematic literature review of studies on frail MM patient management.
• Analysis of treatment effectiveness and adverse events in vulnerable populations.
• Evaluation of frailty and comorbidity assessment in MM treatment planning.

Main Results:

• Frail MM patients are more susceptible to treatment-related stress and adverse events.
• Current treatments require dynamic evaluation of efficacy and toxicity in frail individuals.
• Patient-specific frailty and comorbidities are critical factors in treatment decision-making.

Conclusions:

• Integrating fitness and frailty assessments into standard MM care is crucial.
• Flexible and individualized therapeutic options are necessary for frail MM patients.
• Dynamic monitoring of treatment response and side effects is essential for optimizing care in this population.